Newswise — BOSTON – Dana-Farber Cancer Institute has appointed John Ryan to be its next Senior Vice President, General Counsel and Chief Governance Officer, effective December 14. Ryan has extensive expertise representing health care and life sciences organizations in public company and non-profit settings. He has managed a wide range of legal matters, including medical research and technology, clinical care, IP protection and international expansion.

“John’s sharp mind and deep understanding of the full range of legal issues affecting a complex organization such as Dana-Farber will be a tremendous asset in helping advance our patient care and research goals,” said Laurie H. Glimcher, MD, president and CEO, Dana-Farber Cancer Institute. “I look forward to working with him and the excellent legal team here that he is joining.”

“I am honored and excited to work with Dr. Glimcher and the leadership team at Dana-Farber to advance the mission of eradicating cancer,” Ryan said. “It is a privilege to have the opportunity to build on the extraordinary work that my predecessor, Richard Boskey, has done to support the world-class patient care and research being done at Dana-Farber, and I look forward to joining their talented and accomplished legal team.”

Ryan joins Dana-Farber from The Jackson Laboratory, where he served as General Counsel and Corporate Secretary. He previously held similar roles at Unilife Corporation and Aramark Corporation, and was a Partner at the Philadelphia-based law firm Duane Morris LLP.

Ryan attended New York University, where he graduated with a B.A. cum laude and earned his law degree from Northwestern University. Following law school, John worked as an Assistant District Attorney in Manhattan. Ryan succeeds Richard Boskey, who is retiring as Senior Vice President, General Counsel and Chief Governance Officer after 21 years of service to Dana-Farber.

About Dana-Farber Cancer Institute 

Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest treatments in cancer for adults through Dana-Farber/Brigham and Women’s Cancer Care and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 10 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care. As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering over 1,100 clinical trials.